Dr. Hina Ghafoor is a Board Certified primary care doctor who cares for patients of the Reisterstown, Owings Mills, Westminster and Eldersburg communities at Mercy Personal Physicians at Reisterstown.
Knee replacement surgery is offered at Mercy Medical Center in Baltimore. The orthopedic team at Orthopedics and Joint Replacement at Mercy offer innovative technology for knee replacement surgery.
Mercy's renowned breast center offers award-winning care and Board Certified doctors. The Breast Center's comprehensive care is designed for women undergoing the journey to overcome breast disease.
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
This is a Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (Clinicaltrials.gov ID#: NCT03726879).
This is a research study comparing Atezolizumab (Anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple‑negative breast cancer. (Clinicaltrials.gov ID#: NCT03498716)
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). This study will help to show whether weight loss programs should be a part of breast cancer treatment. (Clinicaltrials.gov ID#: NCT02750826)
This is a phase II randomized trial evaluate the efficacy and Safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment. (Clinicaltrials.gov ID#: NCT03056755)
This is a double-blind, placebo-controlled, randomized phase III study of ipatasertib in combination with paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-altered, locally advanced or metastatic, triple-negative breast cancer or hormone receptor–positive, HER2-negative breast cancer (Clinicaltrials.gov ID#: NCT03337724).
This is a phase III trial to determine how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy and surgery. (Clinicaltrials.gov ID#: NCT02445391)
The purpose of this registry is to create a large-scale, population-based database. This database will match health information to genome information to look at the Agendia Breast Cancer suite and new gene associations. The Agendia Breast Cancer Suite includes MammaPrint® and BluePrint™, which are tests that help your doctor analyze and profile your breast cancer tumor. DiscoverPrint is for research purposes only. (Clinicaltrials.gov ID#: NCT03053193)
This study is researching the link between insulin resistance and breast cancer prognosis in African American and Caucasian women.
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (Clinicaltrials.gov ID#: NCT03701334).
This is a prospective observational study to estimate the incidence of febrile neutropenia among subjects with non-myeloid malignancies at high risk for febrile neutropenia and receiving Neulasta® (Pegfilgrastim) Onpro® kit or other physician choice options for prophylaxis of febrile neutropenia.
This is a non-interventional trial for patients receiving palbociclib for their hormone positive advanced breast cancer. (Clinicaltrials.gov ID#: NCT03280303)
This is a phase III randomized trial evaluate the efficacy and safety of pembrolizumab for women with triple-negative breast cancer who have residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02954874)
Medical Oncology and Hematology at Mercy Medical Center in Baltimore, Maryland, provides diagnosis and treatment for a broad range of cancers including leukemia and lymphoma, neuroendocrine tumors, colorectal cancer, breast cancer, gynecologic cancers, prostate cancer and lung cancer. Drs. David Riseberg, Sandy Kotiah, Richard Huslig, Peter Ledakis and Vinod Varki offer expertise in cancer treatment through chemicals, biological products and immunotherapy, including chemotherapy, chemoembolization, biological and endocrine therapies and radiofrequency abalation.
Medical Oncology and Hematology is part of The Institute for Cancer Care at Mercy Medical Center.
Dr. Vinod Varki is a medical oncologist and hematologist at Medical Oncology and Hematology at Mercy in Baltimore, a division of The Institute for Cancer Care at Mercy.